Brain volume and diffusion markers as predictors of disability and short-term disease evolution in multiple sclerosis

American Journal of Neuroradiology

Volumn 33, Issue 7, 2012, Pages 1356-1362

  Samann P G ^a   Knop, M ^a   Golgor, E ^a,c   Messler, S ^b,d   Czisch, M ^a   Weber, F ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d SYNEOS HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOGRAM; HUMAN; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; SCORING SYSTEM; WHITE MATTER LESION;

ADULT; BRAIN; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; ORGAN SIZE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84865286896     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2972     Document Type: Article

References (59)

1. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006;52:61-76
2. Anderson VM, Fox NC, Miller DH. Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J Magn Reson Imaging 2006;23:605-18
3. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999;12:295-302
4. Miller DH, Barkhof F, Frank JA, et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125:1676-95
5. Rovaris M, Gass A, Bammer R, et al. Diffusion MRI in multiple sclerosis. Neurology 2005;65:1526-32
6. Kalkers NF, Ameziane N, Bot JC, et al. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 2002;59:1572-76
7. Chard DT, Griffin CM, Parker GJ, et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002;125:327-37
8. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003;60:1157-62
9. Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:773-80
10. Sastre-Garriga J, Ingle GT, Chard DT, et al. Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. Neuroimage 2004;22:353-59
11. Richert ND, Howard T, Frank JA, et al. Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis. Neurology 2006;66:551-56
12. De Stefano N, Iannucci G, Sormani MP, et al.MRcorrelates of cerebral atrophy in patients with multiple sclerosis. J Neurol 2002;249:1072-77
13. Bielekova B, Kadom N, Fisher E, et al. MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 2005;65:1071-76
14. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59:1412-20
15. Horakova D, Dwyer MG, Havrdova E, et al. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. J Neurol Sci 2009;282:112-19
16. Ciccarelli O, Werring DJ, Wheeler-Kingshott CA, et al. Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology 2001;56:926-33
17. Tortorella P, Rocca MA, Mezzapesa DM, et al. MRI quantification of gray and white matter damage in patients with early-onset multiple sclerosis. J Neurol 2006;253:903-07
18. Cercignani M, Inglese M, Pagani E, et al. Mean diffusivity and fractional anisotropy histograms of patients with multiple sclerosis. AJNR Am J Neuroradiol 2001;22:952-58
19. Budde MD, Kim JH, Liang HF, et al. Axonal injury detected by in vivo diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis. NMR Biomed 2008;21:589-97
20. Phuttharak W, Galassi W, Laopaiboon V, et al. ADC measurements in various patterns of multiple sclerosis lesions. J Med Assoc Thai 2006;89:196-204
21. Nusbaum AO, Lu D, Tang CY, et al. Quantitative diffusion measurements in focal multiple sclerosis lesions: correlations with appearance on TI-weighted MR images. AJR Am J Roentgenol 2000;175:821-25
22. Vrenken H, Pouwels PJ, Geurts JJ, et al. Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration. J Magn Reson Imaging 2006;23:628-36
23. Tavazzi E, Dwyer MG, Weinstock-Guttman B, et al. Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. Neuroimage 2007;36:746-54
24. Wilson M, Morgan PS, Lin X, et al. Quantitative diffusion weighted magnetic resonance imaging, cerebral atrophy, and disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:318-22
25. Oreja-Guevara C, Rovaris M, Iannucci G, et al. Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study. Arch Neurol 2005;62:578-84
26. Rovaris M, Judica E, Gallo A, et al. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain 2006;129:2628-34
27. Fischer JS, Rudick RA, Cutter GR, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment - National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244-50
28. Cassol E, Ranjeva JP, Ibarrola D, et al. Diffusion tensor imaging in multiple sclerosis: a tool for monitoring changes in normal-appearing white matter. Mult Scler 2004;10:188-96
29. Gallo A, Rovaris M, Riva R, et al. Diffusion-tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis. Arch Neurol 2005;62:803-08
30. Bermel RA, Puli SR, Rudick RA, et al. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol 2005;62:1371-76
31. Tiberio M, Chard DT, Altmann DR, et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 2005;64:1001-07
32. Chard DT, Griffin CM, Rashid W, et al. Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. Mult Scler 2004;10:387-91
33. Paolillo A, Pozzilli C, Giugni E, et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with interferon-beta. Eur J Neurol 2002;9:645-55
34. Quarantelli M, Ciarmiello A, Morra VB, et al. Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. Neuroimage 2003;18:360-66
35. Lukas C, Minneboo A, de Groot V, et al. Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. J Neurol Neurosurg Psychiatry 2010;81:1351-56. Epub 2010 Sep 8
36. Mesaros S, Rocca MA, Sormani MP, et al. Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS: a large scale, short-term follow-up study. J Neurol 2008;255:1378-83
37. Rovaris M, Gallo A, Valsasina P, et al. Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. Neuroimage 2005;24:1139-46
38. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-27
39. Garaci FG, Colangelo V, Ludovici A, et al. A diffusion longitudinal MR imaging study in normal-appearing white matter in untreated relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2007;28:475-78
40. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
41. Chabriat H, Pappata S, Poupon C, et al. Clinical severity in CADASIL related to ultrastructural damage in white matter: in vivo study with diffusion tensor MRI. Stroke 1999;30:2637-43
42. Chard DT, Parker GJ, Griffin CM, et al. The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. J Magn Reson Imaging 2002;15:259-67
43. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479-89
44. Van Leemput K, Maes F, Vandermeulen D, et al. Automated segmentation of multiple sclerosis lesions by model outlier detection. IEEE Trans Med Imaging 2001;20:677-88
45. Cercignani M, Bozzali M, Iannucci G, et al. Magnetisation transfer ratio and mean diffusivity of normal appearing white and grey matter from patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:311-17
46. Griffin CM, Chard DT, Ciccarelli O, et al. Diffusion tensor imaging in early relapsing-remitting multiple sclerosis. Mult Scler 2001;7:290-97
47. van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999;46:747-54
48. Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999;53:1698-704
49. Guttmann CR, Meier DS, Holland CM. Can MRI reveal phenotypes of multiple sclerosis? Magn Reson Imaging 2006;24:475-81
50. Simon JH, Jacobs LD, Campion MK, et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1999;53:139-48
51. Kalkers NF, Vrenken H, Uitdehaag BM, et al. Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue. Mult Scler 2002;8:410-14
52. Kalkers NF, Bergers E, Castelijns JA, et al. Optimizing the association between disability and biological markers in MS. Neurology 2001;57:1253-58
53. Hildebrandt H, Hahn HK, Kraus JA, et al. Memory performance in multiple sclerosis patients correlates with central brain atrophy. Mult Scler 2006;12:428-36
54. Lazeron RH, Boringa JB, Schouten M, et al. Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. Mult Scler 2005;11:524-31
55. Kalkers NF, de Groot V, Lazeron RH, et al. MS functional composite: relation to disease phenotype and disability strata. Neurology 2000;54:1233-39
56. Schmierer K, Altmann DR, Kassim N, et al. Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study. Mult Scler 2004;10:182-87
57. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis: European Study Group on Interferon Beta-1b in Secondary Progressive Multiple Sclerosis. Brain 2000;123(pt 11):2256-63
58. Rovaris M, Confavreux C, Furlan R, et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006;5:343-54
59. Dichgans M, Putz B, Boos D, et al. Role of subvoxel free fluid on diffusion parameters in brain tissue with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and its correlation with physical disability: histogram analysis of standard and fluid-attenuated MR diffusion. AJNR Am J Neuroradiol 2003;24:1083-89